Analysis of clinical effect of albumin-bound paclitaxel combined with radiotherapy in the treatment of esophageal cancer
Objective To observe the clinical effect of albumin-bound paclitaxel combined with radiotherapy in the treatment of esophageal cancer.Methods A total of 64 patients with esophageal cancer were randomly divided into an observation group and a control group each with 32 cases.The control group was treated with conventional paclitaxel neoadjuvant chemotherapy,and the observation group was treated with albumin-bound paclitaxel combined with radiotherapy.The therapeutic effect,incidence of adverse reactions,quality of life and serum tumor markers were compared between the two groups.Results The total effective rate of the observation group was 87.50%,which was higher than 59.38%of the control group(P<0.05).The incidence of adverse reactions in the observation group was 15.63%,which was lower than 53.13%in the control group(P<0.05).The scores of social function,body quality,role function and emotional function in the observation group were(90.76±4.35),(88.25±3.97),(85.35±3.97)and(83.58±4.68)points,which were higher than(80.69±4.35),(78.43±2.75),(76.12±3.36)and(75.67±4.57)points in the control group(P<0.05).The serum levels of carbohydrate antigen 125(CA125),carbohydrate antigen 19-9(CA19-9)and carcinoembryonic antigen(CEA)in the observation group were(28.10±1.54)U/ml,(18.97±1.42)U/ml and(1.42±0.15)ng/ml,which were lower than(29.25±2.06)U/ml,(20.15±2.14)U/ml and(1.74±0.26)ng/ml in the control group(P<0.05).Conclusion The implementation of albumin-bound paclitaxel combined with radiotherapy for the treatment of esophageal cancer patients can reduce the incidence of adverse reactions,enhance the therapeutic effect of the disease,reduce the level of serum tumor markers,and promote the improvement of the patients'quality of life,and is recommended to be promoted.
NETL
NSTL
万方数据
